Gilead Sciences returned for a $46.7m round that will support further development of its biosensor-based diagnostics device.
US-based disease management technology developer Glympse Bio completed a $46.7m series B round yesterday that was led by venture capital firm Section 32 and which included biopharmaceutical company Gilead Sciences.
Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures, Catalio Capital Management, Arch Venture Partners, CRV, GreatPoint Ventures and Polaris Partners’ LS Polaris Innovation Fund filled out the round.
Glympse will use the capital to further development of its biosensor system, which is designed to detect biological changes caused by…
